We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App

Transcutaneous Bilirubin Estimated in ELBW Infants

By LabMedica International staff writers
Posted on 31 Jul 2018
Print article
Image: The Giraffe Blue PT Lite Phototherapy system (Photo courtesy of GE Healthcare).
Image: The Giraffe Blue PT Lite Phototherapy system (Photo courtesy of GE Healthcare).
Hyperbilirubinemia is seen in almost two-thirds of term and more than two-thirds of all preterm infants. The incidence of kernicterus has dramatically decreased since the onset of regular screening and aggressive management with phototherapy (PHT).

Transcutaneous bilirubinometry (TcB) is a quick, painless and reliable alternative to serum bilirubin measurements in the management of hyperbilirubinemia. Following PHT, TcB measurements are considered unreliable, as PHT causes bleaching of the skin.

Pediatricians at the Lucile Salter Packard Children’s Hospital (Palo Alto, CA, USA) and their colleagues enrolled a population that consisted of extremely low birth weight (ELBW) infants born at University of Texas Medical Branch (UTMB, Galveston, TX, USA) receiving phototherapy for hyperbilirubinemia. ELBW infants were defined as infants with a birth weight of less than 1,000 g. A total of 19 infants were enrolled in the study, with a mean gestational age of 26 ± 2 weeks and mean weight 827 ± 127 g.

Prior to starting PHT, an opaque patch was placed on the back of the infant. PHT was started by using a Giraffe Blue Lite PT system and continued for five days. Transcutaneous bilirubin in covered area (TcB-C), and exposed area (TcB-E) and total serum bilirubin (TSB) levels were obtained at birth and every 24 hours for five days. TcB measurements were obtained using the Respironics BiliCheck noninvasive bilirubin meter. Serum bilirubin levels (TSB) were used as the gold standard.

The scientists found that the difference between TcB-C and TSB was 2.68 ± 2.41 mg/dL (mean ± SD), which was significantly different statistically. In contrast, the difference between TcB-E and TSB was − 0.51 ± 1.74 mg/dL, which was also statistically significant. TcB-C consistently overestimates TSB, while TcB-E consistently underestimates TSB. The authors concluded that during PHT exposure, TcB-C does not correlate with TSB values in ELBW infants and that TcB-C levels cannot be used as a surrogate for TSB measurement in ELBW infants. The study was published on July 10, 2018, in the journal BMC Pediatrics.

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay

Print article


Molecular Diagnostics

view channel
Image: Liquid biopsy could detect and monitor aggressive small cell lung cancer (Photo courtesy of Shutterstock)

Blood-Based Test Detects and Monitors Aggressive Small Cell Lung Cancer

Small cell lung cancer (SCLC) is a highly aggressive type of cancer known for its ability to metastasize. The behavior of tumors is largely governed by which genes are turned on, or transcribed, irrespective... Read more


view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more


view channel
Image: The groundbreaking treatment approach has shown promise in hard-to-treat cancers (Photo courtesy of 123RF)

Genetic Testing Combined With Personalized Drug Screening On Tumor Samples to Revolutionize Cancer Treatment

Cancer treatment typically adheres to a standard of care—established, statistically validated regimens that are effective for the majority of patients. However, the disease’s inherent variability means... Read more


view channel
Image: Microscope image showing human colorectal cancer tumor with Fusobacterium nucleatum stained in a red-purple color (Photo courtesy of Fred Hutch Cancer Center)

Mouth Bacteria Test Could Predict Colon Cancer Progression

Colon cancer, a relatively common but challenging disease to diagnose, requires confirmation through a colonoscopy or surgery. Recently, there has been a worrying increase in colon cancer rates among younger... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.